f02aa649-f382-4f91-9a51-ce73199f8fbc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.400
- E2F_TARGETS+0.300
- KRAS_SIGNALING_DN+0.300
- MYC_TARGETS_V1+0.300
- MYC_TARGETS_V2+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PANCREAS_BETA_CELLS+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- FATTY_ACID_METABOLISM+0.200
Top 10 suppressed
- TGF_BETA_SIGNALING-0.500
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.400
- ALLOGRAFT_REJECTION-0.300
- HEDGEHOG_SIGNALING-0.300
- MITOTIC_SPINDLE-0.300
- NOTCH_SIGNALING-0.300
- COMPLEMENT-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- HEME_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NK-A7XE-01A-12R-A405-07 | — | cohortSQ1 | 0.773 |
| 2 | 43c87798-5762-42c1-b7d8-47fc126fc2d3 | — | — | 0.765 |
| 3 | SRR11296848 | — | — | 0.765 |
| 4 | TCGA-E2-A9RU-01A-11R-A41B-07 | — | B | 0.750 |
| 5 | SRR8942959 | — | — | 0.748 |
| 6 | TCGA-AC-A62V-01A-11R-A31O-07 | — | B | 0.744 |
| 7 | R309 | — | — | 0.744 |
| 8 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.743 |
| 9 | TCGA-E2-A14O-01A-31R-A115-07 | — | B | 0.742 |
| 10 | TCGA-77-A5GA-01A-11R-A27Q-07 | — | cohortSQ2 | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |